Zealand Pharma Shares Fall on Obesity Drug Trial Dropout Data
Zealand Pharma shares fell 8.5% after German partner Boehringer Ingelheim reported late-stage clinical trial results for an obesity drug candidate licensed from the Danish biotech, showing a nearly one-fifth patient dropout rate.
Zealand Pharma shares fell after German partner Boehringer Ingelheim reported results from a late-stage clinical trial of an obesity drug candidate licensed from the Danish biotech that showed nearly a fifth of patients dropped out. 5% in European morning trade.